The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer

被引:44
作者
Jin, Anqi [1 ,2 ]
Xu, Jianhao [2 ]
Wang, Yan [3 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Inst Ultrasound Med, Dept Ultrasound Med, Med Reading,Affiliated Peoples Hosp 6, Shanghai, Peoples R China
[2] Soochow Univ, Med Coll, Suzhou, Peoples R China
[3] Shanghai Jiao Tong Univ, Dept Ultrasound Med, Affiliated Peoples Hosp 6, Shanghai Inst Ultrasound Med, Shanghai, Peoples R China
关键词
FNA; TERT; thyroid cancer; BRAF V600E; HIGH PREVALENCE; DISTANT METASTASES; MAJOR INDICATOR; CARCINOMA; TELOMERASE; PREDICTION; HTERT; GENE;
D O I
10.1097/MD.0000000000011548
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Telomerase reverse transcriptase (TERT) promoter mutations have been described in different pathological types of thyroid cancers (TC). After many types of research focusing on the mutations rate in malignant tumors, the main role of TERT promoter mutations has been changed to the preoperative diagnosis and prognosis of TC, according to their high prevalence in aggressive TC. Methods: We searched Pubmed, Web of Science, Scopus, and VHL and reviewed the most common 2 mutations C288T and C250T in different types of TC, the association between them and some specific clinicopathological features, and their significance in preoperative diagnosis and prognosis of TC. we chose 38 studies into our qualitative research. We also chose 22 studies to do a meta-analysis on this subject. Results: The overall rate of these mutations in different types of TC was 10.0%, with 86.1% C228T mutation, 12% C250T mutation, and 2.1% other type mutations. The rate increases significantly as the TC become more aggressive, and reaches 56.8% in anaplastic thyroid cancer (ATC). Statistically meaningful association is found between TERT promoter mutations and older age, larger tumor size, extrathyroidal extension, lymph node metastasis, distance metastasis, advanced TNM stage, recurrence, and BRAF V600E mutation. Some studies concentrating on DNA sequencing based on fine needle aspiration biopsy (FNAB) also proved their significance in preoperative stage, with 7% to 16.5% sensitivity. Conclusions: TERT promoter mutations were likely to occur in BRAF V600E positive TC. Patients with these 2 combined mutations were more likely to have a poor prognosis and outcome. TERT promoter mutations is an essential part of the ThySeq gene panel. The mechanism of how they influence the appearance and development of TC has not been expounded. The next study direction may be the mechanism exploration and the further study to prove their significance in preoperative diagnosis.
引用
收藏
页数:6
相关论文
共 43 条
[1]   Single Point Mutations in Pediatric Differentiated Thyroid Cancer [J].
Alzahrani, Ali S. ;
Murugan, Avaniyapuram Kannan ;
Qasem, Ebtesam ;
Alswailem, Meshael ;
Al-Hindi, Hindi ;
Shi, Yufei .
THYROID, 2017, 27 (02) :189-196
[2]   Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer [J].
Alzahrani, Ali S. ;
Qasem, Ebtesam ;
Murugan, Avaniyapuram Kannan ;
Al-Hindi, Hindi N. ;
AlKhafaji, Dania ;
Almohanna, Mai ;
Xing, Mingzhao ;
Alhomaidah, Doha ;
AlSwailem, Meshael .
THYROID, 2016, 26 (02) :235-241
[3]   Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation [J].
Bae, Ja Seong ;
Kim, Yourha ;
Jeon, Sora ;
Kim, Se Hee ;
Kim, Tae Jung ;
Lee, Sohee ;
Kim, Min-Hee ;
Lim, Dong Jun ;
Lee, Youn Soo ;
Jung, Chan Kwon .
DIAGNOSTIC PATHOLOGY, 2016, 11
[4]  
BELANGER R, 1983, J OTOLARYNGOL, V12, P109
[5]   STRUCTURE AND FUNCTION OF TELOMERES [J].
BLACKBURN, EH .
NATURE, 1991, 350 (6319) :569-573
[6]   TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas [J].
Bullock, Martyn ;
Ren, Yan ;
O'Neill, Christine ;
Gill, Anthony ;
Aniss, Adam ;
Sywak, Mark ;
Sidhu, Stan ;
Delbridge, Leigh ;
Learoyd, Diana ;
de Vathaire, Florent ;
Robinson, Bruce G. ;
Clifton-Bligh, Roderick J. .
CLINICAL ENDOCRINOLOGY, 2016, 85 (02) :283-290
[7]   Clinical and Molecular Features of Hurthle Cell Carcinoma of the Thyroid [J].
Chindris, Ana-Maria ;
Casler, John D. ;
Bernet, Victor J. ;
Rivera, Michael ;
Thomas, Colleen ;
Kachergus, Jennifer M. ;
Necela, Brian M. ;
Hay, Ian D. ;
Westphal, Sydney A. ;
Grant, Clive S. ;
Thompson, Geoffrey B. ;
Schlinkert, Richard T. ;
Thompson, E. Aubrey ;
Smallridge, Robert C. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (01) :55-62
[8]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[9]   The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter [J].
Cong, YS ;
Wen, JP ;
Bacchetti, S .
HUMAN MOLECULAR GENETICS, 1999, 8 (01) :137-142
[10]   Preoperative Assessment of TERT Promoter Mutation on Thyroid Core Needle Biopsies Supports Diagnosis of Malignancy and Addresses Surgical Strategy [J].
Crescenzi, A. ;
Trimboli, P. ;
Modica, D. Cicciarella ;
Taffon, C. ;
Guidobaldi, L. ;
Taccogna, S. ;
Rainer, A. ;
Trombetta, M. ;
Papini, E. ;
Zelano, G. .
HORMONE AND METABOLIC RESEARCH, 2016, 48 (03) :157-162